Colorado recently enacted House Bill 1063, allowing for the prescription, dispensing, use, and marketing of crystalline polymorph psilocybin, contingent upon the approval of a drug by the FDA. This bill was originally created to support behavioral health treatment, particularly treatment-resistant depression.

North Dakota enacted Senate Bill 2064, designating crystalline polymorph psilocybin, including the pharmaceutical composition COMP360, as a Schedule IV controlled substance. This designation recognizes a limited risk of physical or psychological dependence.